FK506-binding protein 12-calcineurin complex (FKBP12-CaN)

The FK506-binding protein 12-calcineurin complex (FKBP12-CaN) is a pivotal signaling assembly that regulates the adaptive immune response [1, 3]. FKBP12 is a 12-kDa immunophilin with peptidyl-prolyl isomerase activity, while calcineurin is a calcium- and calmodulin-dependent serine/threonine phosphatase [7, 10]. This complex is the primary therapeutic target for the immunosuppressant drug tacrolimus (FK506), which acts as a molecular glue by binding to FKBP12 to form a binary complex that subsequently associates with calcineurin [5, 13]. This interaction sterically blocks calcineurin's active site, preventing the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT) [9, 15]. Without dephosphorylation, NFAT cannot translocate to the nucleus to induce the transcription of essential cytokines such as interleukin-2 (IL-2), thereby inhibiting T-cell proliferation [1, 11]. Beyond its role in immunosuppression for organ transplantation and autoimmune diseases, the FKBP12-calcineurin pathway is involved in cardiac development, neuronal signaling, and fungal virulence [2, 16]. However, systemic inhibition of this complex is associated with significant clinical challenges, including nephrotoxicity and neurotoxicity, due to the widespread expression of calcineurin in non-immune tissues [7, 8].

Other names

FKBP12-calcineurin complexFKBP12-PP2B complexFKBP1A-calcineurin complexFK506-binding protein 12-calcineurin complexFKBP-12–calcineurin

Tacrolimus binds to FKBP12 to form a binary complex that subsequently binds to and inhibits the phosphatase activity of calcineurin by sterically hindering substrate access, thereby preventing the dephosphorylation and nuclear translocation of NFAT and the subsequent production of pro-inflammatory cytokines [1, 10, 15].